The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma

Tomonari Kinoshita, Junji Yoshida, Genichiro Ishii, Keiju Aokage, Tomoyuki Hishida, Kanji Nagai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Large cell neuroendocrine carcinoma of the lung and SCLC are collectively classified as high-grade NECs. However, there have been few reports focusing on the differences of clinicopathological prognostic factors between resectable LCNEC and SCLC. Patients and Methods: We reviewed the clinical data of 140 patients who underwent complete resection of high grade NEC in our institute and analyzed the clinicopathological features in relation to their survival. Results: There were no statistically significant differences in overall and recurrence-free survival between pure and combined subtypes in either LCNEC or SCLC. In LCNEC, larger tumor diameter (P =.01), nodal metastasis (P <.01), lymphatic permeation (P <.01), and vascular invasion (P =.01) were unfavorable prognostic factors. However, in SCLC, tumor diameter and vascular invasion were not prognostic factors, but nodal metastasis (P <.01) and lymphatic permeation (P =.03) were strongly correlated with poor prognosis. Conclusion: There were no apparent differences in biological behavior between pure and combined subtypes in either LCNEC or SCLC. Lymphatic involvement was an important unfavorable prognostic factor in SCLC, whereas tumor diameter, vascular invasion, and lymphatic involvement had a poor prognostic effect in LCNEC.

Original languageEnglish
Pages (from-to)535-540
Number of pages6
JournalClinical Lung Cancer
Volume14
Issue number5
DOIs
Publication statusPublished - 2013 Sep
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Small Cell Lung Carcinoma
Blood Vessels
Neoplasm Metastasis
Neoplasms
Survival
Recurrence
Lung

Keywords

  • Biological behavior
  • High grade neuroendocrine carcinomas
  • Large-cell neuroendocrine carcinoma
  • Pathological diversity
  • Prognostic factors
  • Small-cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma. / Kinoshita, Tomonari; Yoshida, Junji; Ishii, Genichiro; Aokage, Keiju; Hishida, Tomoyuki; Nagai, Kanji.

In: Clinical Lung Cancer, Vol. 14, No. 5, 09.2013, p. 535-540.

Research output: Contribution to journalArticle

@article{614054dcb8b049978036463729ff298f,
title = "The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma",
abstract = "Introduction: Large cell neuroendocrine carcinoma of the lung and SCLC are collectively classified as high-grade NECs. However, there have been few reports focusing on the differences of clinicopathological prognostic factors between resectable LCNEC and SCLC. Patients and Methods: We reviewed the clinical data of 140 patients who underwent complete resection of high grade NEC in our institute and analyzed the clinicopathological features in relation to their survival. Results: There were no statistically significant differences in overall and recurrence-free survival between pure and combined subtypes in either LCNEC or SCLC. In LCNEC, larger tumor diameter (P =.01), nodal metastasis (P <.01), lymphatic permeation (P <.01), and vascular invasion (P =.01) were unfavorable prognostic factors. However, in SCLC, tumor diameter and vascular invasion were not prognostic factors, but nodal metastasis (P <.01) and lymphatic permeation (P =.03) were strongly correlated with poor prognosis. Conclusion: There were no apparent differences in biological behavior between pure and combined subtypes in either LCNEC or SCLC. Lymphatic involvement was an important unfavorable prognostic factor in SCLC, whereas tumor diameter, vascular invasion, and lymphatic involvement had a poor prognostic effect in LCNEC.",
keywords = "Biological behavior, High grade neuroendocrine carcinomas, Large-cell neuroendocrine carcinoma, Pathological diversity, Prognostic factors, Small-cell lung carcinoma",
author = "Tomonari Kinoshita and Junji Yoshida and Genichiro Ishii and Keiju Aokage and Tomoyuki Hishida and Kanji Nagai",
year = "2013",
month = "9",
doi = "10.1016/j.cllc.2013.04.003",
language = "English",
volume = "14",
pages = "535--540",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma

AU - Kinoshita, Tomonari

AU - Yoshida, Junji

AU - Ishii, Genichiro

AU - Aokage, Keiju

AU - Hishida, Tomoyuki

AU - Nagai, Kanji

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: Large cell neuroendocrine carcinoma of the lung and SCLC are collectively classified as high-grade NECs. However, there have been few reports focusing on the differences of clinicopathological prognostic factors between resectable LCNEC and SCLC. Patients and Methods: We reviewed the clinical data of 140 patients who underwent complete resection of high grade NEC in our institute and analyzed the clinicopathological features in relation to their survival. Results: There were no statistically significant differences in overall and recurrence-free survival between pure and combined subtypes in either LCNEC or SCLC. In LCNEC, larger tumor diameter (P =.01), nodal metastasis (P <.01), lymphatic permeation (P <.01), and vascular invasion (P =.01) were unfavorable prognostic factors. However, in SCLC, tumor diameter and vascular invasion were not prognostic factors, but nodal metastasis (P <.01) and lymphatic permeation (P =.03) were strongly correlated with poor prognosis. Conclusion: There were no apparent differences in biological behavior between pure and combined subtypes in either LCNEC or SCLC. Lymphatic involvement was an important unfavorable prognostic factor in SCLC, whereas tumor diameter, vascular invasion, and lymphatic involvement had a poor prognostic effect in LCNEC.

AB - Introduction: Large cell neuroendocrine carcinoma of the lung and SCLC are collectively classified as high-grade NECs. However, there have been few reports focusing on the differences of clinicopathological prognostic factors between resectable LCNEC and SCLC. Patients and Methods: We reviewed the clinical data of 140 patients who underwent complete resection of high grade NEC in our institute and analyzed the clinicopathological features in relation to their survival. Results: There were no statistically significant differences in overall and recurrence-free survival between pure and combined subtypes in either LCNEC or SCLC. In LCNEC, larger tumor diameter (P =.01), nodal metastasis (P <.01), lymphatic permeation (P <.01), and vascular invasion (P =.01) were unfavorable prognostic factors. However, in SCLC, tumor diameter and vascular invasion were not prognostic factors, but nodal metastasis (P <.01) and lymphatic permeation (P =.03) were strongly correlated with poor prognosis. Conclusion: There were no apparent differences in biological behavior between pure and combined subtypes in either LCNEC or SCLC. Lymphatic involvement was an important unfavorable prognostic factor in SCLC, whereas tumor diameter, vascular invasion, and lymphatic involvement had a poor prognostic effect in LCNEC.

KW - Biological behavior

KW - High grade neuroendocrine carcinomas

KW - Large-cell neuroendocrine carcinoma

KW - Pathological diversity

KW - Prognostic factors

KW - Small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84883782699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883782699&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.04.003

DO - 10.1016/j.cllc.2013.04.003

M3 - Article

C2 - 23792008

AN - SCOPUS:84883782699

VL - 14

SP - 535

EP - 540

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -